P

PharmChem Inc
OTC:PCHM

Watchlist Manager
PharmChem Inc
OTC:PCHM
Watchlist
Price: 3.75 USD 0.27% Market Closed
Market Cap: $17.3m

Balance Sheet

Balance Sheet Decomposition
PharmChem Inc

Balance Sheet
PharmChem Inc

Rotate your device to view
Balance Sheet
Currency: USD
Dec-1997 Dec-1998 Dec-1999 Dec-2000 Dec-2001 Dec-2002 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
0
1
2
2
0
4
2
3
2
2
Cash Equivalents
0
1
2
2
0
4
2
3
2
2
Total Receivables
8
7
7
8
5
4
1
1
1
1
Accounts Receivables
8
7
7
8
5
4
1
1
1
1
Other Receivables
0
0
0
0
0
0
0
0
0
0
Inventory
2
2
2
2
2
1
0
0
0
0
Other Current Assets
0
1
1
1
3
1
0
0
0
0
Total Current Assets
10
10
12
13
11
10
3
4
3
3
PP&E Net
8
9
10
11
13
12
0
0
0
0
PP&E Gross
8
9
10
11
13
12
0
0
0
0
Accumulated Depreciation
10
11
11
9
8
9
0
0
0
0
Intangible Assets
0
0
0
0
0
0
0
0
0
0
Goodwill
3
3
3
3
1
1
0
0
0
0
Other Long-Term Assets
1
1
1
1
4
0
0
0
0
0
Other Assets
3
3
3
3
1
1
0
0
0
0
Total Assets
22
N/A
22
-1%
25
+14%
27
+9%
28
+5%
23
-20%
3
-85%
4
+20%
3
-32%
3
-1%
Liabilities
Accounts Payable
3
3
3
4
6
3
0
0
0
0
Accrued Liabilities
3
4
4
4
2
3
0
0
0
0
Short-Term Debt
4
2
0
1
5
3
0
0
0
0
Current Portion of Long-Term Debt
1
0
1
1
3
2
0
0
0
0
Other Current Liabilities
0
0
0
0
2
0
0
0
0
0
Total Current Liabilities
11
10
9
10
17
11
1
0
1
1
Long-Term Debt
1
1
3
2
3
1
0
0
0
0
Other Liabilities
0
1
0
0
1
0
0
0
0
0
Total Liabilities
12
N/A
11
-7%
11
+2%
12
+8%
22
+77%
12
-43%
1
-96%
0
-18%
1
+25%
1
+5%
Equity
Common Stock
19
19
19
0
0
0
0
0
0
0
Retained Earnings
9
8
5
4
13
9
11
10
10
10
Additional Paid In Capital
0
0
0
19
20
20
14
14
13
12
Treasury Stock
0
0
0
0
0
0
0
0
0
0
Other Equity
0
0
0
0
0
0
0
0
0
0
Total Equity
10
N/A
11
+7%
14
+26%
15
+9%
7
-55%
10
+54%
3
-73%
4
+28%
2
-39%
2
-3%
Total Liabilities & Equity
22
N/A
22
-1%
25
+14%
27
+9%
28
+5%
23
-20%
3
-85%
4
+20%
3
-32%
3
-1%
Shares Outstanding
Common Shares Outstanding
6
6
6
6
6
6
5
5
5
5
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett